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IT should be emphasised that it is not only new drugs that can give rise to
adverse reactions. In a recent survey in Belfast (Hurwitz and Wade, 1969) it
was found that 19.8 per cent of patients treated with digoxin suffered adverse
reactions to it, and that adverse reactions to digitalis accounted for one third of
all drug reactions monitored. Withering in 1785 was aware of the fact that the
drug he had pioneered was not without hazard and wrote "it is better the
world should derive some instruction, however imperfect from my experience
than that the lives of men should be hazarded by its unguarded exhibition, or
that medlicine of so much efficacy should be condemned and reject as dangerous
and unmanageable."
I. THE NEED FOR DRUG CoNTROL AUTHORITIES
(i) The beginning of monitoring of drug hazards
The objective assessment and measurement of the efficacy of drug therapy is a
recent discipline. Attempts to measure and assess the ill effects of drug therapy
are recent and as yet can hardy be called a discipline. Yet it was in 1877 at
a meeting in Manchester that the British Medical Association initiated the first
collaborative study of the adverse reaction;s of a drug. A committeel was set up to
investigate the sudden unexpected deaths which sometimes occurred during the
induction of chloroform anaesthesia (McKendrick Coats & Newman 1880). Since
that time there has always been some concern amongst doctors about adverse
reactions to drugs; and reactions to smallpox vaccine, typhoid vaccine and more
recently poliomyelitis vaocines have been a continual source of anxiety not only
to doctors but also to the public, whose fears have somet4imes been fanned to great
emotional heights by anti-vivisectionists and anti-vaccinationists. At the end of
the First World War, an epidemic of jaundice and fatal hepatic necrosis amongst
soldiers treated for syphilis with organic arsenicals was so serious that it was the
subject of a special report by the Medical Research Committee predecessor of the
present Medical Research Council (Medical Research Council, 1922). And a few
years later it was recognised that fatal jaundice could be caused by cinchophen, a
remedy used in the treatment of gout (Worster-Drought, 1923; Short & Bauer,
1933), and agranulocytosis by tho analgesic drug amidopyrine (aminophenazone;
aminopyrine; Pyramidon) (Madison & Squier, 1933; Kracke & Parker, 1934).
The introduction of the sulphonamides to medicine in the late 1930's brought
familiarity with adverse reactions to all doctors. But these drugs, penicillin, strepto-
111mycin and the corticosteroids led to such advances in the efficacy of medical treat-
ment that the adverse reactions although recognised, caused no great anxiety.
ThMis state of affairs was changed in 1961 by the thalidomide catastrophe (Mellin &
Katzenstein, 1962). This tragedy left its mark not only on the unfortunate children
but also on the medical profession, the pharmaceutical industry, the public and on
governments. Now it is recognised that there is an urgent need to determine not
only the adverse reactions that a drug may cause but the incidence of those react-
ions in relation to the use of the drug, and to determine sections of the population
at greater than average risk (D'Arcy and Griffin, 1972).
(ii) The Thaidomide disaster
In view of the historic importance in terms of legislation it might well be desir-
able to spend some time describing the spectrum of thalidomide toxicity.
(a) Thyroid dysfunction
The first adverse reaction reported caused by thalidomide, oddly enough was the
least important and that was the development of myxoedema. This reIport was made
in 1959.
(b) Neuropathy
Early in 1960 isolated reports were receivedl by Burley of Distillers Company
(Biochemicals) Limited, from various parts of Great Britain describing symptoms
and signs suggestive of peripheral neuritis occurring in patients receiving thalido-
miide regularly for periods of six monthis or more. Florence, however, recorded the
first report in the literature in December 1960. In four patients polyneuritis had
developed while they were taking thalidomide, and he thought that the symptoms
could possibly be a toxic effect of the drug. Kuenssberg et at soon added five
similar cases in January 1961. It was not till the more detailed report of Fullerton
and Kremer in September 1961 that the association of thalidomnide and resulting
neuropathy became fully realised in Great Britain.
(c) Teratogenicity
In December 1959 Weidenbach presented the case history of a girl born on
November 10, 1958, to a twenty-four-year-old primigravida. The upper and lower
limbs were missing. The hands and feet originated directly from the shoulder and
pelvic girdle respectively. There were also deformities of the digits. No additional
abnormalities were noted. The infant progressed very well in the nursery and con-
tinued to develop in accordance with her age. The history of the gestation yielded
nothing unusual. Neither parent could recall a family history of malformation.
Although it was recognised that no conclusion regarding the aetiology of the mal-
formation ould be drawn it was thought that, owing to the symmetry and involve-
ment of all extremities, a hereditary factor was most likely.
Kosenow and Pfeiffer, at the September 1960 meeting of the German Society
of Paediatrics in Kassel, had a scientific exhibit describing two infants with similar
malfrmations and also micromelia, hemangioma of the midline of the face and
duodenal stenosis.
In September 1961, Wiedemann presented a paper calling attention to the current
112increase in the incidence of hypoplastic and aplastic malformations of the extremi-
ties. Over a period of ten months he had seen thirteen patients. He was aware of
twenty-seven similar cases in his area. Since no hereditary signs appeared in the
histories of any of his thirteen patients he considered an exogenous cause that
must have come into effect around .the beginning of 1959. He questioned whether
a drug among the constant flow of new drugs entering the market, might have
been involved.
Pfeiffer and Kosenow presented a paper on the question of exogenous causes of
severe malformations of the extremi.ties to the North Rhein-Westphalia Paediatric
Meeting in Dusseldorf on November 18, 1961. They mentioned! thirty-four newborn
infan.ts with defects of the long bones seen at the Children's Hospital at Muenster
from January 1, 1960 to November 18, 1961. After their presentations Lenz, of
Hamburg, raised the question of thalidomide consumption by the mothers. This
was later reviewed, and it was found that a large number of the mothers involved
had taken thalidomide.
The Fetal Life Study received an inquiry in 1962 concerning the incidence of
phocomelia in relation to a recent increase that had been observed in West
Germany. The Fetal Life Study was established in 1946 in a selected population
at the Columbia-Presbyterian Medical Center as a long-term prospective epidemlio-
logic investigation of human reproduction, to determine the incidence of foetal
deaths, neonatal deaths and congenital malformations and to dellineate associated
factors. From more than 10,000 pregnancies prospectively followed in the years
1946 to 1960 and more than 2,000 followed in 1961 the group was unable to find
any causes of phocomelia similar to the pictures appearing in the literature. A
possilble explanation of this discrepancy became apparent at a Rhein-Westphalia
paediatric meeting in Dusseldorf, Germany on November 18, 1961. Dr. Lenz of
Hamburg, suggested that this malformation was related to the ingestion early in
pregnancy of the drug thalidomide (alpha-(N-phthalimido)glutarimide).
It was not long, however, before individual case reports began to appear. These
cases also illustrated the problem of retrospective epidemiology. In one situation
the drug had to be retrieved from a former neighbour. In another case, in which
the mother had been included in a hospital-study prospective survey, the fact that
she was given thalidomide was not known by her family doctor. In retrospect
studies two out of three family doctors could not rememiber whether thalidomide
had been taken.
Several communications indicated that small doses might be devastating. One
patient who was a week overdue for a menstrual period took 50 mg of thalidomide
a day for one week only; her premature baby had phocomelia. In another report
the mother apparently received 100 mg of thalidomide for three nights and 50 mg
for two nights in the second week of pregnancy; the baby was born with phoco-
melia. If the dates in these situations were correct these may illustrate the earliest
stages of pregnancy in which teratogenic effects should be sought in -the assessment
of teratogenicity. It is even more worrying that in these cases the drug was exerting
its teratogenic effect in women who did not even know for certain that they were
pregnant.
113(iii) The continual appearance af new hazards and new dimensions of adverse
reactions
The first confirmed reports of the transplacental transmission of cancer in man
by means of a hormone, stilboestrol have recently been published. The evidence
provided by this extremely important research and its significance need immediate
and careful assessment.
Recently Herbst and Scully (1970) reported seven cases of adenocarcinoma of
the vagina in adolescent girls in the New England area during a period of four
years. The patients' ages ranged from 15 to 22 years. They had symptoms of
irregular vaginal bleeding for up to oncl year. Five were treated by radical surgery
and one by wide excision. AU were alive one to four years after operation. The
seventh, in whom the disease was too far advanced at surgical exploration, died
within six months. The authors were puzzled about the causation of this apparent
clustering of cases, as carcinoma of the vagina is uncommon and usually occurs at
a much older age.
An eighth case was added in a retrospective study of factors that might have been
associated wi-th the appearance of these tumours. Herbst and colleagues (1971)
noticed that maternal bleeding when the girl's mother was pregnant with the patient
and in previous pregnancies was more common than in a control group. But of
greater siignificance than that was the finding that seven of the eight mothers had
been treated with diethylstilboestrol during the first trimester of the material preg-
nancy, while none of the control group was so treated. A separate study by P.
Greenwald and colleagues has now confirmed this association, adding five more
cases in which the actual dosage of synthetic oestrogen used has been obtained.
All 13 patients were born between l946 and 1953, a period when stilboestrol was
being given for repeated or threatened abortion. All the mothers who took stil-
boestrol began treatment in the first two months of pregnancy. They received either
a constant dose administered throughout pregnancy or a continually increasing dose
given almost to term. The actual dosage varied but followed roughly that suggested
by A. W. Smith beginning at 5 mg'by mouth during the sixth or seventh week of
pregnancy and increasing by 5 mg at two-weekly intervals to the 15th week, when
25 mg daily was being given. The dose then increased by 5 mg at weekly intervals
until the 35;th week, at which time as much as 125 mg of stilboestrol was being taken
by mouth daily.
The original series of seven cases exceeded the number of cases in the entire
world literature for a tumour of this type in adolescent girls born before 1945.
Indeed, adenocarcinoma of the vagina was thought to have some relationship to
vaginal remants. Moreover, if these neoplasms were the result simiply of high-risk
pregnancies, this should have become apparent before 1945. It was therefore
suspected that exposurd to stilboestrol and vagina carcinoma in the offspring might
have a cause-and-effect relationship. The suggestion is reinforced by the fact that
stilboestrol was used only infrequently in general obstetric practice. Even at the
Boston Hospital for Women, where a special high-risk pregnancy clinic was being
conducted on-ly about one in twenty-one patients delivered in the wards had
received stilboestrol during the five year period 1946 to 1951. Thus when the
expectancy of a chance association is less than 5 per cent, the occurrence of
114maternal stilboestrol therapy in 12 out of 13 cases of vaginal adenocarcinoma in
young women cannot be considered coincidental.
II. BACKGROUND TO DRUG CONTROL IN THE UNITED KINGDOM
The role of the Medicines Act 1968 can probably best be understood against the
historical perspective of attempts by the government to control the use of potent
pharmacologically active agents in terms of quality and efficiency.
The Gin Acts of the 18th century introduced the concept of control over sales
and supply, recognised the necessity of protecting the community and pioneered
later efforts to overcome the misuse and abuse of drugs.
The British Pharmacopoeia was first published in the 19th century. Successive
editions and addenda up to the present day have produced standards of quality
control, which have justly enjoyed international prestige. Unfortunately, there has
never been an adequate machinery for the enforcement of these high standards.
The Dangerous Drugs Acts recognised the risks of drug addiction, and introduced
the idea of control of manufacture under licence, together with strict recording of
sale and supply.
The Phariacy and Poisons Acts and the introduction of the Poisons Rules,
elaborated the theme of control over sale and supply. Though designed primarily
to deal with poisons; medicines were later included. The control of poisons and
medicines by similar rules has been cumbersome and fraught with difficulties, but
it has helped to maintain some control in a long process of transition.
The Therapeutic Substances Acts added new concepts to control. The design
was the control of substances such as vaccines or sera, the purity and potency of
which could not be controlled by chemical means. Such control was difficult to con-
tain within a pharmacopoeial monograph, fior it demanded the use of biological
standardisation, requiring standard materials, against which the products could
be assayed. Many of these standard materials are now international.
T'he Therapeutic Substances Acts (T.S.A.) further recognised that the personnel
and the conditions of the premises in which such products were manufactured
were as imiportant in control as the tests which could be applied to the end-product.
Thus factory inspection and in-process control played an integral part in the
considerations for the issue of a licence under the Acts and their regulations, either
to manufacture or to import. For the first time primary consideration's of safety
began toemerge for these Actsenvisaged notonly the purity and potency of prepara-
tions, but allowed the restriction by prescription to any medicines, which would be
a hazard to the community if freely available.
The Cancer and Veneral Diseases Acts were enacted to prevent the public
advertisement and promotion of medicines for these serious conditions, thus
preventing not only fraudulent claims bu.t protecting the sufferers from inadequate
and unsuitable treatment. In this way the control of advertisement and promotional
literature for medicines was begun.
It was in thils multiplicity of legislation that even before the establishment of the
Committee on Safety of Drugs in 1963 that concepts of quality control, restrictions
115over sale and supply, of in-process control, and control over promotion and
advertisement and of manufacture under licence were born. However, there was
considerable complexity of control under the different acts. Although such statutes
and regulations as the Pharmacy and Poisons Acts, the Dangerous Drugs Act and
the Poisons Rules contralled the sale and supply of some medicines, others came
under the control of the Therapeutic Substances Act, and no central agency existed
that gave consideration to all medicines, so far as their safety for use in man was
concerned. Although everything pointed to the need to consolidate the legislation
on medicines, the old machinery seemed to work and for decades no great problem
had arisen. The task of preparing consolidating legislation was formidable and
disentangling the comnplex machine was a daunting venture.
Lulled into security by the quiet years, both public and Government were unipre-
pared for the therapeutic explosion of the last thirty years. This complacency was
rudely shattered by the thalidomide tragedy. The conscience of the public was
troubled and the Government galvanised into activity. No existing legislation was
availlable to take care of this new consideration, and to consider these new con-
cepts of safety and at the same time to produce comprehensive and consolidating
legislation was bound to be lengthy and time-consuming. In the meantime, some-
thing had to be done, for any product could be marketed, with a few exiceptions
under the Therapeutic Substances Acts, however dangerous or ill tested it might be.
As an interim measure in 1963 the Minister of Health, on advice, established
the Committee on Safety of Drugs. The Committee consisted of a panel of indepen-
dent experts from various fields of Pharmacy, Patbhology, etc .and served under
the chairmanship of firstly Sir Derrick Dunlop and more recently Professor Scowen.
TIe Committee was serviced by a professional secretariat of pharmacists and
medical officers who under took the assessment of the submissions and presented
these to the Committee and various sub-committees.
The Committee on Safety of Drugs was set up in June 1963 by the Health
Minister, in consultation wilth the medical and pharmaceutical professions and the
British Pharmaceutical Industry, with the follcowing terms of reference: -
(i) "To invite from the manufacturer or other person developing or proposing to
market a drug in the United Kingdom any reports they may think fit on the toxicity
tests carried out on it; to consider whether any further tests should be made and
whet-her the drug should be sutbmitted to clinical trials; and to convey their advice
to those who submitted reports.
(ii) To obtain reports of clinical trials of drugs submitted thereto.
(iii) Taking into account the safety and efficacy of each drug, and the purposes for
which it is to be used, to consider whether it may be released for marketing, with
or without precautions or restrictions on its use; and to convey their advice to
those who submitted reports.
(iv) To give to manufacturers and others concerned any general advice they may think
fit.
(v) To assemble and assess reports abou-t adverse effects of drugs in use and prepare
information thereon which may be brought to the notice of doctors and others
concerned.
(vi) To advise the appointing Ministers on any of the above matters."
The Committee had no legal powers, but worked with the voluntary agreement
of the Association of British Pharmaceutical Industry and the Proprietary Associa-
tion of Great Britain. TIhey promnised that none of their members would! put on
116clinical trial or release for marketing a new drug against the advice of the Commit-
tee, whose advice they would always seek.
An effective drug control authority should have adequate machinery for assess-
ment in three broad functional areas:
(i) scrutiny before clinical trial
(ii) scrutiny before marketing
(iii) surveillance of each drug after marketing so that adverse reactions can be
adequately monitored and documented, and if necessary a warning issued to
the medical profession.
A strong sub-committee structure was set up, drawing in a wide variety of exper-
tise, which could not be contained within a single committee of workable size.
Sub-committees were first formed to advise on toxicity and clinical trials, and in
adverise reactions. Later it became necessary to form an advisory group of experts
on vaccines and biochemicals.
When an application from a manufacturer was received it could largely be classi-
fied into a reformulation or Minor Submission, and a New Drug or Major Sub-
mission. These submissions were requesting either permission to market or to con-
duct clinical trials. The submission was assessed by a pharmacilst and then by a
senior medical officer of the professional secretariat. A summary was prepared and
the submission and summary circulated, to members of the appropriate sub-com-
mittee before the sub-committee meetings where the data was presented by the
Senior Medical Officer dealing with the submission and this was discussed and
recommendations were then passed from the sub-committee to the main com-mittee,
after which a decision was made and the manufacturer informed.
Clinical Trial
Before clinical trial can be considered full information is required on the chemils-
try, pharmacodynamics, metabolism, acute and intermed.iate toxicity, on teratology
and in drug interactions. If the pharmacodynamic studies indicate a therapeutic
potential and the committee is satisfied with the quality and safety of the drug, no
objection is raised to clinical trial. The nature of the trial is the responsibility of the
applicant, provided always that the committee can be satised that the staff respon-
sible for the trial and facilities available to them are appropriate.
Although a pamphlet, "Notes for the guidance of manufacturers and other
persons developing or proposing to market a drug in the United, Kingdom" was
available, the Committee did not 'lay down rigid requirements for the pre-clinical
toxicity testing programme of new drugs. This was the responsibility of the manu-
facturer, although the Committee's staff were always available for consultation on
the proposals.
The pharmocodynamic properties and therapeutic potential of the new drug
are studied and considered in relationship to its metabolism, the pattern of toxicity
and its teratogenic potential. Ideally the toxicological and teratological studies
should be performed in species that are known to metaboliise the drug in the same
way as man. Unfortunately, this information on the metabolism is seldom available
at this stage and toxicity testing is most frequently performed in the rat and dog
and teratogenicity studies on the rat and rabbit. Both toxicological testing
117and teratogenicity studies should be performed at three dose levels by the
intended route or routes of administration of the new drug. In the toxicological
studies the doses should be so adjusted that the low dose is within the range of
the proposed therapeutic dose, the high dose so designed that the toxicity of the
drug is manifested and the target organ identified. Intermediate term toxicity studies,
defined as studies involving less than half the animal's Iife-span, are required for two
or more species, most commonly the rat and the dog. Detailed haematological and
clinical chemistry monitoring is regarded as a pre-requisite of modern toxicology,
as are detailed terminal histopathological studies of major organs. If the toxicity
tests indicate that one particular organ shows signs of dysfunction, the clinical
monitoring of the subsequent trial should involve intensive monitoring of that par-
ticular organ, and assurances should be sought that clinical investigation will pro-
ceed cautiously. If organ enlargement is a feature of the toxicity studies, histopatho-
logical work should be undertaken to find out whether this is a functional hyper-
trophy or a manifestation of toxicity.
The general recommendations for teratological studies are modest, involving
administration of the test drug, during the period of organogenesis, at three dose-
levels to two species, usually the rabbit and rat. Evidence should be presented that
the strain of animal used produces abnormal offspring following the administration
of a known teratogen such as thalidomide. Other investigations such as fertility
studies are conducted at the discretion of the applicant.
Marketing
When clinical trials have been completed and a request is received for marketing,
the assessment will be based largely on the clinical documentation in relation to the
proposed clinical use. In the early clinical studies evidence will have been obtained
on the absorption, distribution, metabolism and excretion of the drug. In addition,
the clinical pharmacology will have been studied, when appropriate.
TIhe preparations of the drug proposed for marketing must show an adequate
stability and uniformity of content. It must be clearly demonstrated that methods
of formulation and preparation do not modify the drug action or interfere with
its biological availability.
Evidence will be sought in the documentation for any sign of possible organ
toxicity which might be revealed from t;he monitoring by haematological and clinical
chemical methods. Problems of possible interactions with other drugs must also
be scrutinised. In addition at this stage if the drug is intended for prolonged use
additional studies will be required of long-term toxicity in animals.
Finally, the proposed promotional literature is examined to ensure that in the
view of the committee no extravagant or misleading claims are made and that the
necessary precautions and contra-indications are adequately expressed.
Adverse Reaction Reporting
The surveillance of drugs after marketing is directed by the Sub-Committee on
Adverse Reactions. The primary mechanism for monitoring is based on a voluntary
and spontaneous reporting system, using a simple, reply-paid 'yellow-card' whereby
doctors and dentists are encouraged to report any suspected adverse reactions to
118drugs to the Committee. Contact between the Committee and its staff now moved
away from the pharmaceutical industry through its medical advisers, to the practis-
ing doctor whether in hospital or in general practice. The number of reports of
suspected adverse reactions to drugs is a disappointingly low proportion of the
total, and the true incidence of even major reactions is as yet not well documented.
The fraction reported to the Committee just constitutes the tip of the iceberg, most
of which remains submerged beneath the surface of our awareness (Dunlop, 1969).
Collaboration with the World Health Organisation drug monitoring schemes is
well established as is also contact with drug regulating authorities in Europe and
the F.D.A. in the U.S.A. and Canadian F.D.D.
THE MEDICINEs Acr 1968
The Medicines Act of 1968 has resulted in the translation of Committee on
Safety of Drugs into the newly formed Committee on Safey of Medicines. An
identical sub-committee structure exists but with the addition of a sub-committee
on Chemistry, Pharmacy and Standards. Its functions and procedures will differ
little from that of its predecssor but it will act as the advisory committee to the
Licensing Authority.
The Licensing Authority will issue in effect five major groups of licences:
(a) Licences of Right
(i) Product Licen.ces-these are applicable to a product already on sale on the
duly appointed day, namely Ist September, 1971.
(ii) Clinical Trials Certificate-applicable to drugs already undergoing clinical
trial with the approval of the Comnittee on Safety of Drugs on the duly
appointed day.
(b) Clinical Trial Certificates
Valid for a period of two years for drugs approvad by the Committee on Safety
of Medicines for clinical trial.
(c) Product Licence
Valid for a period of five years on drugs approved for marketing by the Com-
mittee on Safety of Medicines.
Under the Medicines Act new provisions are introduced which control manufac-
ture, distribution, and storage of drugs, and to cover these provisions a medicines
inspectorate has been established and manufacturers and wholesale dealers have to
hold appropriate licences.
(d) Manufacturer' Licence.
(e) Wholesale Dealers' Licence.
The Licensing Authority issue "Notes on Application for Cli-nical Trial Certifi-
cates" and "Notes on Application for Product Licences" as a guide to manufac-
turers of the nature of the data required.However like the previous Conmnittee
on Safety of Drugs no firm recommendations are laid down since the assessment of
new drugs is a constantly chan-ging iscene in the light of new developments and the
awareness of new hazards.
CONCrLUSION
"The Committee has thus endeavoured to safeguard the sick by ensuring that
new medicines are adequately tested, before they are introduced for trial: by
ensuring that the preparations are constant and appropriate before marketing, and
that their therapeutic potential outweighs any possible hazards: and that the
claims are reasonable, and the precautions outlined. In addition, it maintains
119a close surveillance after narketing, so that any unexpected or unusual effects may
be recognised at the earliest opportunity and the professions informed of them.
The Committee, however, would be failing in its task of safeguarding the sick,
if its attention was totally focussed on aspects of safety alone. For absolute safety
cannot exist and the more potent the remedy, the more may be the capacity for
harm. This is a difficult road to travel for the sick are not safeguarded if undue
restriction and caution impedes therapeutic advance, and constant care is required
to ensure that no -patient shall be deprived of any potential therapeutic advance
even at an early stage of development if an urgent need arises." (Scowren 1971).
Quite clearly the standard of safety or freedom from toxicity must be greater for
a drug which is used% for a trivial indication, e.g., a headache than for a drug that
is effective in poten;tially life threatening condition.
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